Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
For Your Education and Enjoyment 2 Small-Cap Biotechs That Could Reward Patient InvestorsWritten by Chris Markoch. Published 12/12/2025. 
Key Points - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investing and patience rarely go hand in hand. If you're considering the small-cap biotech sector, patience is essential. Most of these companies are still in the clinical stage and do not have commercially available drugs or therapeutics. That also means many of these firms report negative earnings and little to no revenue. Success often hinges on the outcome of a single clinical-stage drug or therapeutic. For the everyday American who's worked hard to build their nest egg, Trump preserved a IRS loophole that allows you to protect your retirement savings before billions in American wealth are lost.
Download Your Free 2026 Wealth Protection Guide and execute the simple steps to protect your future. GET THE FREE GUIDE Even when a product advances through trials, profitability can still be years away. Only after reaching that milestone do companies typically attract the analyst coverage and institutional investment that can materially lift their valuations. But landing an early winner in this space can be highly rewarding. A successful small-cap biotech can deliver 3x, 5x, or even 10x returns. Many investors approach this like a numbers game, spreading capital across several biotech penny stocks to diversify risk. With that in mind, here are two small-cap biotech stocks that carry significant risks but also offer the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company focused on epigenetics-based tests for early cancer detection. Unlike many penny stocks in the space, Mainz has a commercially available product: ColoAlert, the first DNA-based screening tool for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, a leading digital-health pioneer in Germany. With more than 60,000 new colorectal cancer cases annually in Germany, the commercial opportunity is meaningful. Mainz Biomed is also developing a non-invasive, blood-based screening test for early detection of pancreatic cancer and reported positive topline results from a feasibility study in October. That program, however, remains years from potential commercial approval. Risks are substantial. ColoAlert is not yet available in the United States, and despite early European sales and expansion plans into South America, revenue remains limited. The company disclosed "going concern" language in its Sept. 26 SEC filing and has since filed a $150 million mixed shelf offering. That financing activity has helped keep the MYNZ share price above $1 and out of immediate delisting danger. Mainz Biomed is racing to generate sustainable revenue. If it succeeds, even a relatively small investment could produce a sizable return. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is a micro-cap biotech pursuing a potentially disruptive antiviral approach, but it also carries the financial risks that speculative investors must consider. The company is developing a novel class of therapies based on its proprietary "nanoviricide" platform. These candidates are designed to mimic human cell surfaces and lure viruses into binding with them, neutralizing pathogens before they can infect real cells. If validated in human trials, this approach could represent a fundamentally new method for treating infectious diseases. NanoViricides' pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced and has shown encouraging preclinical antiviral activity. Like many micro-cap biotechs, NanoViricides is pre-revenue and relies on fresh capital to advance its programs. The company reported limited cash on hand in recent filings, so investors should expect the possibility of future dilution. Still, if even one candidate successfully advances into clinical development, the valuation upside could be substantial. For investors with patience and a high tolerance for risk, NNVC represents a genuine moonshot in the antiviral space.
| 
